Onxeo

Onxeo SA is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through a unique mechanism of action in the highly sought-after DNA Damage Response (DDR) field. The company focuses on advancing first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point that attracts potential partners.